Patients' Perceptions of Biosimilars: A Systematic Review.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
08
08
2023
medline:
23
10
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
To systematically summarize and evaluate the findings of existing studies about patients' perceptions of biosimilars by assessing their attitudes and knowledge. We conducted a systematic review of published studies concerning patients' perceptions of biosimilars, using databases of China National Knowledge Infrastructure, SinoMed, Web of Science, PubMed, Embase, and Cochrane Library. Two independent reviewers screened a total of 2197 Chinese or English papers published between 1 January 2018, and 1 October 2022. We assessed the quality of the included studies by applying the Joanna Briggs Institute appraisal tools. Forty-three studies were included in the review, with the majority originating from Europe (n = 22) and North America (n = 10). Of these studies, 37 were cross-sectional quantitative studies, three were quasi-experimental studies, and the remaining three were qualitative studies based on semi-structured interviews. The sample sizes of the included studies ranged from 9 to 6554 patients. Twenty-two out of 31 studies investigating patients' acceptance of biosimilars found that most participants expressed satisfaction with treatment using biosimilars. However, doubts about the clinical effects and regulatory approval pathway could negatively influence patients' attitudes. The majority of patients understood the economic advantages of biosimilars; however, some incorrectly connected lower prices with lower quality. Patients generally lacked knowledge about biosimilars. There were 6-51% of participants who were familiar with biosimilars, and 25-58% thought they did not know enough about biosimilars. Physicians, pharmacists, medicines agencies, academia, and patient associations were identified as the main sources of information on biosimilars for patients. Healthcare providers not informing or advising patients about switching may hinder patients from acquiring enough knowledge. The majority of patients expressed satisfaction with treatment using biosimilars, but limited knowledge continued to impede their perceptions. Doubts about the clinical effects and regulatory approval pathway were identified as major factors that negatively influenced patients' attitudes towards biosimilars, while the impact of a price advantage was mixed. It is essential to maintain a focus on educating healthcare professionals about biosimilars, including their clinical outcomes and the regulatory pathway, which equips them to provide comprehensive and informed guidance to patients.
Identifiants
pubmed: 37676537
doi: 10.1007/s40259-023-00620-7
pii: 10.1007/s40259-023-00620-7
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-841Subventions
Organisme : Peking Union Medical College
ID : PUMC Public Health (2019) 22
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9(7):699. https://doi.org/10.6004/jadpro.2018.9.7.2 .
doi: 10.6004/jadpro.2018.9.7.2
pubmed: 31249718
pmcid: 6570521
Antman EM, Creager MA, Houser SR, Warner JJ, Konig M. American Heart Association principles on the accessibility and affordability of drugs and biologics: a presidential advisory from the American Heart Association. Circulation. 2017;136(24):e441–7. https://doi.org/10.1161/CIR.0000000000000551 .
doi: 10.1161/CIR.0000000000000551
pubmed: 29122813
Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–705. https://doi.org/10.1002/bit.26438 .
doi: 10.1002/bit.26438
pubmed: 28842986
pmcid: 5698755
Safdar A, Butt MH, Ahmad A, Zaman M. Progress in oncology biosimilars till 2020: scrutinizing comparative studies of biosimilar monoclonal antibodies. J Oncol Pharm Pract. 2021;27(5):1195–204. https://doi.org/10.1177/10781552211016083 .
doi: 10.1177/10781552211016083
pubmed: 34096401
Triantafyllidi E, Triantafillidis JK. Systematic review on the use of biosimilars of trastuzumab in HER2+ breast cancer. Biomedicines. 2022;10(8):2045. https://doi.org/10.3390/biomedicines10082045 .
doi: 10.3390/biomedicines10082045
pubmed: 36009592
pmcid: 9405693
Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, et al. Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC). J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.510 .
doi: 10.1200/JCO.2017.35.15_suppl.510
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260–5. https://doi.org/10.1200/jco.2017.77.4893 .
doi: 10.1200/jco.2017.77.4893
pubmed: 29443651
Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, et al. Regulatory and clinical experiences with biosimilar filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019;24(4):537–48. https://doi.org/10.1634/theoncologist.2018-0341 .
doi: 10.1634/theoncologist.2018-0341
pubmed: 30842244
pmcid: 6459242
Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–3. https://doi.org/10.1001/jamainternmed.2020.0338 .
doi: 10.1001/jamainternmed.2020.0338
pubmed: 32227137
pmcid: 7105946
Mouslim MC, Trujillo AJ, Alexander GC, Segal JB. Association between filgrastim biosimilar availability and changes in claim payments and patient out-of-pocket costs for biologic filgrastim products. Value Health. 2020;23(12):1599–605. https://doi.org/10.1016/j.jval.2020.06.014 .
doi: 10.1016/j.jval.2020.06.014
pubmed: 33248515
pmcid: 7748066
Lobo F, Río-Álvarez I. Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain. Pharmaceuticals (Basel). 2021;14(3):283. https://doi.org/10.3390/ph14030283 .
doi: 10.3390/ph14030283
pubmed: 33809934
Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, et al. The expiry of Humira
doi: 10.3389/fphar.2020.591134
pubmed: 33519450
Okoro RN. Biosimilar medicines uptake: the role of the clinical pharmacist. Explor Res Clin Soc Pharm. 2021;1: 100008. https://doi.org/10.1016/j.rcsop.2021.100008 .
doi: 10.1016/j.rcsop.2021.100008
pubmed: 35479506
pmcid: 9031038
Druedahl LC, Almarsdóttir AB, KälvemarkSporrong S, De Bruin ML, Hoogland H, Minssen T, et al. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nat Biotechnol. 2020;38(11):1253–6. https://doi.org/10.1038/s41587-020-0717-7 .
doi: 10.1038/s41587-020-0717-7
pubmed: 33144720
Druedahl LC, KälvemarkSporrong S, van de Weert M, De Bruin MLM, Hoogland H, Minssen T, et al. Evolving biosimilar clinical requirements: a qualitative interview study with industry experts and European national medicines agency regulators. BioDrugs. 2021;35:351–61. https://doi.org/10.1007/s40259-021-00478-7 .
doi: 10.1007/s40259-021-00478-7
pubmed: 33830478
Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https://doi.org/10.3389/fphar.2019.00279 .
doi: 10.3389/fphar.2019.00279
pubmed: 30983996
pmcid: 6447826
Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. https://doi.org/10.1136/annrheumdis-2012-202603 .
doi: 10.1136/annrheumdis-2012-202603
pubmed: 23467636
Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Effect Resour. 2019;17(1):1–10. https://doi.org/10.1186/s12962-019-0174-7 .
doi: 10.1186/s12962-019-0174-7
Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):655–66. https://doi.org/10.1080/14737167.2020.1794826 .
doi: 10.1080/14737167.2020.1794826
pubmed: 32657174
Tubic B, Marković-Peković V, Jungić S, Allocati E, Godman B. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: findings and implications. Med Access Point Care. 2021;5: 23992026211027692. https://doi.org/10.1177/23992026211027692 .
doi: 10.1177/23992026211027692
pubmed: 36204505
pmcid: 9413607
Peyrin-Biroulet L, Lonnfors S, Avedano L, Danese S. Changes in inflammatory bowel disease patients’ perspectives on biosimilars: a follow-up survey. United Eur Gastroenterol. 2019;7(10):1345–52. https://doi.org/10.1177/2050640619883704 .
doi: 10.1177/2050640619883704
Pineles D, Arsuaga A, Malter LB, Bosworth BP, Hudesman DP, Chang S. Patient perceptions regarding the use of biosimilars in inflammatory bowel disease. Am J Gastroenterol. 2017;112:S418–9. https://doi.org/10.14309/00000434-201710001-00750 .
doi: 10.14309/00000434-201710001-00750
Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. Rheumatol Ther. 2019;6(2):195–206. https://doi.org/10.1007/s40744-019-0144-8 .
doi: 10.1007/s40744-019-0144-8
pubmed: 30790242
pmcid: 6514039
Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One. 2017;12(4): e0175826. https://doi.org/10.1371/journal.pone.0175826 .
doi: 10.1371/journal.pone.0175826
pubmed: 28410403
pmcid: 5391967
Smastuen MC, Brandvold M, Andenaes R. Is patients’ satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey. Ann Rheum Dis. 2018;77:86. https://doi.org/10.1136/annrheumdis-2018-eular.5993 .
doi: 10.1136/annrheumdis-2018-eular.5993
Young D, Cummings F, Latter S. Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study. Eur J Hosp Pharm. 2022. https://doi.org/10.1136/ejhpharm-2022-003371 .
doi: 10.1136/ejhpharm-2022-003371
pubmed: 35853694
Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927–32. https://doi.org/10.1016/j.semarthrit.2018.07.005 .
doi: 10.1016/j.semarthrit.2018.07.005
pubmed: 30093238
Gasteiger C, Scholz U, Petrie KJ, Dalbeth N. A bio-what? Medical companions’ perceptions towards biosimilars and information needs in rheumatology. Rheumatol Int. 2022;42(11):1993–2002. https://doi.org/10.1007/s00296-021-05037-5 .
doi: 10.1007/s00296-021-05037-5
pubmed: 34705051
Frantzen L, Cohen J-D, Trope S, Beck M, Munos A, Sittler M-A, et al. Patients’ information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine. 2019;86(4):491–6. https://doi.org/10.1016/j.jbspin.2019.01.001 .
doi: 10.1016/j.jbspin.2019.01.001
pubmed: 30659920
Kovitwanichkanont T, Raghunath S, Wang D, Kyi L, Pignataro S, Morton S, et al. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Intern Med J. 2020;50(3):374–7. https://doi.org/10.1111/imj.14753 .
doi: 10.1111/imj.14753
pubmed: 32141205
Wu Q, Lian Z, Wang X, Cheng H, Sun J, Yu H, et al. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients: evidence from China. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2022.1044798 .
doi: 10.3389/fphar.2022.1044798
pubmed: 37841938
pmcid: 10577175
Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–9. https://doi.org/10.1080/03007995.2018.1560221 .
doi: 10.1080/03007995.2018.1560221
pubmed: 30618353
Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer Adher. 2017;11:519–30. https://doi.org/10.2147/ppa.S129333 .
doi: 10.2147/ppa.S129333
Mohd Sani N, Aziz Z, Panickar R, Kamarulzaman A. Pharmacists’ perspectives of biosimilars: a systematic review. BioDrugs. 2022;36(4):489–508. https://doi.org/10.1007/s40259-022-00541-x .
doi: 10.1007/s40259-022-00541-x
pubmed: 35776294
Sarnola K, Merikoski M, Jyrkkä J, Hämeen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5): e034183. https://doi.org/10.1136/bmjopen-2019-034183 .
doi: 10.1136/bmjopen-2019-034183
pubmed: 32371511
pmcid: 7228507
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12. https://doi.org/10.18553/jmcp.2019.25.1.102 .
doi: 10.18553/jmcp.2019.25.1.102
pubmed: 30589628
Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars. Part I: improving biosimilar understanding and adoption. BioDrugs. 2020;34(6):783–96. https://doi.org/10.1007/s40259-020-00452-9 .
doi: 10.1007/s40259-020-00452-9
pubmed: 33141421
pmcid: 7669769
JBI. Checklist for analytical cross sectional studies; 2020. https://jbi.global/sites/default/files/2021-10/Checklist_for_Analytical_Cross_Sectional_Studies.docx . Accessed 19 Aug 2023.
JBI. Checklist for quasi-experimental studies; 2020. https://jbi.global/sites/default/files/2021-10/Checklist_for_Quasi-Experimental_Appraisal_Tool%20%281%29.docx . Accessed 19 Aug 2023.
Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015;13(3):179–87. https://doi.org/10.1097/xeb.0000000000000062 .
doi: 10.1097/xeb.0000000000000062
pubmed: 26262565
Makhlouf SM, Pini S, Ahmed S, Bennett MI. Managing pain in people with cancer: a systematic review of the attitudes and knowledge of professionals, patients, caregivers and public. J Cancer Educ. 2020;35(2):214–40. https://doi.org/10.1007/s13187-019-01548-9 .
doi: 10.1007/s13187-019-01548-9
pubmed: 31119708
Poudel P, Griffiths R, Wong VW, Arora A, Flack JR, Khoo CL, et al. Oral health knowledge, attitudes and care practices of people with diabetes: a systematic review. BMC Public Health. 2018. https://doi.org/10.1186/s12889-018-5485-7 .
doi: 10.1186/s12889-018-5485-7
pubmed: 29716561
pmcid: 5930945
Vandenplas Y, Barbier L, Simoens S, Van Wilder P, Vulto AG, Huys I. Perceptions about biosimilar medicines among Belgian patients in the ambulatory care. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2021.789640 .
doi: 10.3389/fphar.2021.789640
pubmed: 36188534
pmcid: 9523170
Varma M, Almarsdottir AB, Druedahl LC. “Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients’ perceptions of biosimilars. Basic Clin Pharmacol. 2022;130(5):581–91. https://doi.org/10.1111/bcpt.13719 .
doi: 10.1111/bcpt.13719
Kaneko K, Prieto-Alhambra D, Jacklin C, Bosworth A, Dickinson S, Berry S, et al. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations. BMJ Open. 2022. https://doi.org/10.1136/bmjopen-2021-050949 .
doi: 10.1136/bmjopen-2021-050949
pubmed: 36574984
pmcid: 9806034
Azevedo A, Bettencourt A, Selores M, Torres T. Biosimilar agents for psoriasis treatment: the perspective of Portuguese patients. Acta Medica Port. 2018;31(9):496–500. https://doi.org/10.20344/amp.10127 .
doi: 10.20344/amp.10127
van Overbeeke E, De Beleyr B, de Hoon J, Westhovens R, Huys I. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447–59. https://doi.org/10.1007/s40259-017-0244-3 .
doi: 10.1007/s40259-017-0244-3
pubmed: 28929342
De Somer T, Deprez N, Baert D, Deceuninck M, Huys I, Mattens V, et al. Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting. J Crohns Colitis. 2021;15:S406. https://doi.org/10.1093/ecco-jcc/jjab076.520 .
doi: 10.1093/ecco-jcc/jjab076.520
Macaluso FS, Leone S, Previtali E, Ventimiglia M, Armuzzi A, Orlando A, et al. Biosimilars: the viewpoint of Italian patients with inflammatory bowel disease. Dig Liver Dis. 2020;52(11):1304–9. https://doi.org/10.1016/j.dld.2020.07.028 .
doi: 10.1016/j.dld.2020.07.028
pubmed: 32807691
Martinez-Mugica Barbosa C, Rodriguez de Castro B, Labeaga Beramendi Y, Terroba Alonso P, Barbazan Vazquez J. Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. Eur J Hosp Pharm. 2021;28(2):109–11. https://doi.org/10.1136/ejhpharm-2019-001999 .
doi: 10.1136/ejhpharm-2019-001999
Tischer B, Mehl A. Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adher. 2018;12:1413–24. https://doi.org/10.2147/ppa.S169339 .
doi: 10.2147/ppa.S169339
Aladul MI, Fitzpatrick RW, Chapman SR. Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs. 2017;31(5):439–46. https://doi.org/10.1007/s40259-017-0238-1 .
doi: 10.1007/s40259-017-0238-1
pubmed: 28752242
Thakur K, Biberger A, Handrich A, Rezk MF. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in Europe. Rheumatol Ther. 2016;3(2):245–56. https://doi.org/10.1007/s40744-016-0048-9 .
doi: 10.1007/s40744-016-0048-9
pubmed: 27817152
pmcid: 5127972
Karlsdottir K, Gunnarsdottir AI, Grondal G, Love TJ, Stefansdottir E, Davidsdottir LG, et al. A patients’ perspective towards the injection devices for Humira
doi: 10.3389/fmed.2022.799494
pubmed: 35155495
pmcid: 8829031
Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Dig Liver Dis. 2020;52(3):281–8. https://doi.org/10.1016/j.dld.2019.09.012 .
doi: 10.1016/j.dld.2019.09.012
pubmed: 31648920
Hastier-De Chelle A, Cluzeau V, Condat J, Arab N, Hebuterne X, Filippi J. Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study. Gastroenterology. 2019;156(6):S955–6.
doi: 10.1016/S0016-5085(19)39345-X
Harvey RD, McGrath M, Cook JW, Dixon MD, Pentz RD. How will the cost of biosimilars affect patients’ willingness to receive them? J Clin Oncol. 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.e18338 .
doi: 10.1200/JCO.2019.37.15_suppl.e18338
pubmed: 31116674
pmcid: 6675596
Ismailov RM, Khasanova ZD, Gascon P. Knowledge and awareness of biosimilars among oncology patients in Colorado, USA. Future Oncol. 2019;15(22):2577–84. https://doi.org/10.2217/fon-2019-0194 .
doi: 10.2217/fon-2019-0194
pubmed: 31339051
Ighani A, Wang JY, Manolson MF. An evaluation of psoriasis patient perceptions and understanding of biosimilars: a Canadian survey comparing biologic and nonbiologic users. J Cutan Med Surg. 2018;22(3):365–7. https://doi.org/10.1177/1203475417746337 .
doi: 10.1177/1203475417746337
pubmed: 29608867
Yossef L, Wright M, Benedict J, Morris GA, McNicol M, Boyle B, et al. Patient and caregivers’ perspectives on biosimilar use in pediatric inflammatory bowel disease. J Pediatr Gastr Nutr. 2022;75(1):59–63. https://doi.org/10.1097/mpg.0000000000003462 .
doi: 10.1097/mpg.0000000000003462
Papautsky EL, Carlson M, Johnson SM, Montague H, Attai DJ, Lustberg MB. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients. Breast Cancer Res Treat. 2022;194(1):25–33. https://doi.org/10.1007/s10549-022-06615-2 .
doi: 10.1007/s10549-022-06615-2
pubmed: 35568748
pmcid: 9107314
Wilkins AR, Venkat MV, Brown AS, Dong JP, Ran NA, Hirsch JS, et al. Patient perspectives on biosimilar insulin. J Diabetes Sci Technol. 2014;8(1):23–5. https://doi.org/10.1177/1932296813515132 .
doi: 10.1177/1932296813515132
pubmed: 24876533
pmcid: 4454100
Chau J, Delate T, Ota T, Bhardwaja B. Patient perspectives on switching from infliximab to infliximab-dyyb in patients with rheumatologic diseases in the United States. ACR Open Rheumatol. 2019;1(1):52–7. https://doi.org/10.1002/acr2.1007 .
doi: 10.1002/acr2.1007
pubmed: 31777780
pmcid: 6858025
Socal MP, Garrett JB, Tayler WB, Bai G, Anderson GF. Naming convention, interchangeability, and patient interest in biosimilars. Diabetes Spectr. 2020;33(3):273–9. https://doi.org/10.2337/ds19-0065 .
doi: 10.2337/ds19-0065
pubmed: 32848349
pmcid: 7428664
Hu Y, Song Z, Jiang D, Zhuo L, Cheng Y, Zhao R. Knowledge, attitudes and practice of healthcare providers, healthcare regulatory practitioners and patients toward biosimilars in China: insights from a nationwide survey. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.876503 .
doi: 10.3389/fphar.2022.876503
pubmed: 36744212
pmcid: 9816435
Sung Y-K, Jung S-Y, Kim H, Choi S, Im SG, Lee YS, et al. Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world. PLoS One. 2020. https://doi.org/10.1371/journal.pone.0227960 .
doi: 10.1371/journal.pone.0227960
pubmed: 33270667
pmcid: 7714242
Dadkhahfar S, Ohadi L, Rahimi Y, Robati RM, Shekarabi M, Zargari O, et al. Patients’ perception, and adherence to treatment with biosimilar adalimumab in psoriasis. Dermatol Ther. 2022. https://doi.org/10.1111/dth.15227 .
doi: 10.1111/dth.15227
pubmed: 36070217
Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lonnfors S, et al. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Ther Adv Gastroenterol. 2021. https://doi.org/10.1177/17562848211013249 .
doi: 10.1177/17562848211013249
Graham-Clarke PL, Hauber B, Boeri M, Leonardi F, Burge RT, Fernandez M, et al. Patient preferences for biologic and biosimilar osteoporosis treatments in Colombia. Patient Prefer Adher. 2020;14:1049–64. https://doi.org/10.2147/ppa.S250745 .
doi: 10.2147/ppa.S250745
Gasteiger C, Lobo M, Dalbeth N, Petrie KJ. Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatol Int. 2021;41(1):163–71. https://doi.org/10.1007/s00296-020-04576-7 .
doi: 10.1007/s00296-020-04576-7
pubmed: 32300866
Gasteiger C, Jones ASK, Kleinstauber M, Lobo M, Horne R, Dalbeth N, et al. Effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care Res. 2020;72(9):1323–30. https://doi.org/10.1002/acr.24012 .
doi: 10.1002/acr.24012
Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adher. 2016;10:937–48. https://doi.org/10.2147/ppa.S104891 .
doi: 10.2147/ppa.S104891
Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England. Commissioning framework for biological medicines (including biosimilar medicines); 2017. https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf . Accessed 12 Jun 2023.
Azuz S, Newton M, Bartels D, Poulsen BK. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars. Eur J Clin Pharmacol. 2021;77(10):1495–501. https://doi.org/10.1007/s00228-021-03155-4 .
doi: 10.1007/s00228-021-03155-4
pubmed: 34008071
pmcid: 8440249
Jensen TB, Bartels D, Saedder EA, Poulsen BK, Andersen SE, Christensen MMH, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35–40. https://doi.org/10.1007/s00228-019-02765-3 .
doi: 10.1007/s00228-019-02765-3
pubmed: 31677117
Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32:397–404. https://doi.org/10.1007/s40259-018-0306-1 .
doi: 10.1007/s40259-018-0306-1
pubmed: 30269270
pmcid: 6182448
Dutt K, Srinivasan A, Van Langenberg D. The nocebo effect in a non-medical switching program from originator to biosimilar infliximab in inflammatory bowel disease. BioDrugs. 2022;36(5):639–44. https://doi.org/10.1007/s40259-022-00548-4 .
doi: 10.1007/s40259-022-00548-4
pubmed: 35960446
Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, et al. Consensus report: clinical recommendations for the p revention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharm Ther. 2019. https://doi.org/10.1111/apt.15223 .
doi: 10.1111/apt.15223
Germain V, Scherlinger M, Barnetche T, Schaeverbeke T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis. 2020;79(1): e11. https://doi.org/10.1136/annrheumdis-2018-214374 .
doi: 10.1136/annrheumdis-2018-214374
pubmed: 30352888
Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307(6):567–8. https://doi.org/10.1001/jama.2012.115 .
doi: 10.1001/jama.2012.115
pubmed: 22318275
pmcid: 6909539
D’Amico F, Pouillon L, Argollo M, Hart A, Fiorino G, Vegni E, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group. Dig Liver Dis. 2020;52(2):138–42. https://doi.org/10.1016/j.dld.2019.11.004 .
doi: 10.1016/j.dld.2019.11.004
pubmed: 31812570
Costa-Font J, Rico A. Vertical competition in the Spanish national health system (NHS). Public Choice. 2006;128(3–4):477–98. https://doi.org/10.1007/s11127-005-9011-y .
doi: 10.1007/s11127-005-9011-y
Berdud M, Cabases JM, Nieto J. Incentives and intrinsic motivation in healthcare. Gac Sanit. 2016;30(6):408–14. https://doi.org/10.1016/j.gaceta.2016.04.013 .
doi: 10.1016/j.gaceta.2016.04.013
pubmed: 27321370
Gasteiger C, Petrie KJ. Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars. Res Soc Admin Pharm. 2022;18(10):3860–3. https://doi.org/10.1016/j.sapharm.2022.03.009 .
doi: 10.1016/j.sapharm.2022.03.009
Iosifescu A, Halm EA, McGinn T, Siu AL, Federman AD. Beliefs about generic drugs among elderly adults in hospital-based primary care practices. Patient Educ Couns. 2008;73(2):377–83. https://doi.org/10.1016/j.pec.2008.07.012 .
doi: 10.1016/j.pec.2008.07.012
pubmed: 18706784
pmcid: 2739237
Veronin M. Packaging and labeling of pharmaceutical products obtained from the Internet. J Med Internet Res. 2011;13(1):265–76. https://doi.org/10.2196/jmir.1441 .
doi: 10.2196/jmir.1441
Schillinger D, Machtinger EL, Wang F, Palacios J, Rodriguez M, Bindman A. Language, literacy, and communication regarding medication in an anticoagulation clinic: a comparison of verbal vs. visual assessment. J Health Commun. 2006;11(7):651–64. https://doi.org/10.1080/10810730600934500 .
doi: 10.1080/10810730600934500
pubmed: 17074733
Beck M, Michel B, Rybarczyk-Vigouret MC, Leveque D, Sordet C, Sibilia J, et al. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: results of a French web-based survey. MAbs. 2017;9(2):384–91. https://doi.org/10.1080/19420862.2016.1267087 .
doi: 10.1080/19420862.2016.1267087
Okoro RN, Hedima EW, Aguiyi-Ikeanyi CN. Knowledge, attitudes, and practices of pharmacists toward biosimilar medicines in Nigeria. J Am Pharm Assoc. 2022;62(1):79-85.e2. https://doi.org/10.1016/j.japh.2021.09.014 .
doi: 10.1016/j.japh.2021.09.014
Shakeel S, Hassali MA, Rehman H, Rehman AU, Muneswarao J. Knowledge, attitude, and practice towards biosimilars and interchangeable products: a prescriptive insight by the pharmacists. Int J Gen Med. 2020;13:1075–82. https://doi.org/10.2147/ijgm.S266545 .
doi: 10.2147/ijgm.S266545
pubmed: 33204142
pmcid: 7667000
Smith B, Magnani JW. New technologies, new disparities: the intersection of electronic health and digital health literacy. Int J Cardiol. 2019;292:280–2. https://doi.org/10.1016/j.ijcard.2019.05.066 .
doi: 10.1016/j.ijcard.2019.05.066
pubmed: 31171391
pmcid: 6660987
Nutbeam D, McGill B, Premkumar P. Improving health literacy in community populations: a review of progress. Health Promot Int. 2018;33(5):901–11. https://doi.org/10.1093/heapro/dax015 .
doi: 10.1093/heapro/dax015
pubmed: 28369557
Baur C, Martinez LM, Tchangalova N, Rubin D. A review and report of community-based health literacy interventions. Community-based health literacy interventions: proceedings of a workshop. Washington DC: National Academies Press (US); 2018.